Gardasil: two deaths after HPV vaccine


The EMEA ( European Medicines Agency ) has received reports of deaths in women who had previously received Gardasil, including two reports concerning the sudden and unexpected deaths of two young women in the European Union.

Gardasil is a vaccine approved in the European Union for the prevention of cervical cancer and other diseases caused by human papillomavirus ( HPV ) types 6, 11, 16 and 18.

It is estimated that about 1.5 million patients have been vaccinated with this HPV vaccine in Europe.
The two European cases were reported as part of the continuous monitoring of the safety of medicines.
One of the cases occurred in Austria and the other in Germany. In both cases, the cause of death could not be identified. No causal relationship has been established between the deaths of the young women and the administration of Gardasil.

On the basis of the currently available evidence, the EMEA’s Committee for Medicinal Products for Human Use ( CHMP ) is of the opinion that the benefits of Gardasil continue to outweigh its risks and that no changes to its product information are necessary.

The approved indication in the EU for Gardasil is: “ Gardasil is a vaccine for the prevention of high-grade cervical dysplasia ( CIN 2/3 ), cervical carcinoma, high-grade vulvar dysplastic lesions ( VIN 2/3 ), and external genital warts ( condyloma acuminata ) causally related to human papillomavirus types 6, 11, 16 and 18. The indication is based on the demonstration of efficacy of Gardasil in adult females 16 to 26 years of age and on the demonstration of immunogenicity of Gardasil in 9- to 15-year old children and adolescents. Protective efficacy has not been evaluated in males. “

Source: EMEA, 2008

XagenaMedicine_2008



Indietro

Altri articoli

UCSD ( University of California San Diego ) researchers have identified the molecular mechanism activated by the presence of tetrahydrocannabinol...


Human papillomavirus ( HPV ) causes nearly all cervical cancers and some cancers of the vagina, vulva, penis, anus, and...


Although adolescent girls are the main population for prophylactic human papillomavirus ( HPV ) vaccines, adult women who remain at...


Determining vaccine dose-level protection is essential to minimize program costs and increase mass vaccination program feasibility. Currently, a 3-dose vaccination...


The objective of a study was to measure the effectiveness of the quadrivalent human papillomavirus ( HPV ) vaccine against...


Merck & Co has announced that in the pivotal phase III efficacy study, its investigational 9-valent HPV vaccine ( V503...


A commonly-used HIV drug has been shown to kill off the human papillomavirus ( HPV ) that leads to cervical...


Initial vaccinations for human papillomavirus ( HPV ) at a young age is important for maximizing quadrivalent HPV vaccine effectiveness...


The FDA ( Food and Drug Administration ) has approved the vaccine Gardasil for the prevention of anal cancer and...


In a commentary published in the Canadian Medical Association Journal ( CMAJ ), Abby Lippman, an epidemiologist at McGill University...